Expression and its clinicopathological significance of Survivin, MSH2 and MSH6 in colorectal cancer

Objective To analyze the changes of Survivin, MSH6 and MSH2 expression in colorectal cancer and explore their relationship with clinical and pathological parameters. Methods 197 cases of colorectal adenocarcinoma and 20 cases of inflammatory intestinal mucosa were detected by immunohistochemistry with Survivin, MSH6 and MSH2, and the correlation between Survivin, MSH6 and MSH2 expression was analyzed. Results In the control group of 20 cases with inflammatory non-tumor intestinal mucosa, the positive expression rate of MSH2, MSH6, Survivin were 95%, 95%, 10%, respectively. While the positive expression rate of MSH2, MSH6, Survivin were 88.3%, 74.1% and 84.3% in 197 cases of colorectal cancer. Survivin positive expression rate in colorectal cancer group was significantly higher than that in inflammatory control group (P 0.05). MSH2 expression was correlated with tumor size and lymph node metastasis (P 0.05). MSH6 expression was related to gender and lymph node metastasis (P 0.05). Colorectal cancer tissues showed positive correlation between MSH6 and MSH2 (r=0.326, P<0.01), positive correlation between MSH2 and Survivin positive expression (r=0.277, P<0.01), and positive correlation between MSH6 and Survivin positive expression (r=0.435, P<0.01). Conclusions The positive expression rate of Survivin in colorectal cancer is high. MSH2, MSH6 and Survivin in colorectal cancer play an important role in the development and progression of colorectal cancer, and can provide evidence for the detection of these three factors, including metastasis risk, prognosis assessment and clinical treatment. In particular, Survivin gene may provide evidence for gene therapy. Key words: Colorectal neoplasms; MutS homolog 2 protein; MutS homolog 6 protein; Survivin